In the BioHarmony Drug Report Database
Etelcalcetide
Parsabiv (velcalcetide) is a protein pharmaceutical. Velcalcetide was first approved as Parsabiv on 2016-11-11. It has been approved in Europe to treat secondary hyperparathyroidism. It is known to target extracellular calcium-sensing receptor. Parsabiv’s patents are valid until 2034-06-27 (FDA).
Trade Name
|
Parsabiv |
|---|---|
Common Name
|
velcalcetide |
ChEMBL ID
|
CHEMBL3545184 |
Indication
|
secondary hyperparathyroidism |
Drug Class
|
Peptides |
Image (chem structure or protein)